435 results on '"Garrett-Mayer, Elizabeth"'
Search Results
2. A pilot randomized controlled trial to evaluate a survivorship care planning intervention for head and neck cancer survivor-caregiver dyads
3. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials
4. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations
5. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
6. Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Chemotherapy.
7. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
8. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer
9. Oncologistsʼ Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer
10. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
11. Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
12. Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
13. Characterizing the Increase in Artificial Intelligence Content Detection in Oncology Scientific Abstracts From 2021 to 2023.
14. Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR).
15. An assessment of racial differences in epidemiological, clinical and psychosocial factors among head and neck cancer patients at the time of surgery
16. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
17. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
18. State Tobacco Policies as Predictors of Evidence-Based Cessation Method Usage : Results From a Large, Nationally Representative Dataset
19. Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress
20. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
21. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
22. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
23. Perceptions of Snus Among US Adult Smokers Given Free Product
24. One-Year Smoking Trajectories Among Established Adult Smokers With Low Baseline Motivation to Quit
25. CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
26. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
27. Development and implementation of the SUM breast cancer cell line functional genomics knowledge base
28. Bone mineral density during pregnancy in women participating in a randomized controlled trial of vitamin D supplementation
29. The differential impact of state tobacco control policies on cessation treatment utilization across established tobacco disparities groups
30. Gene Expression Alterations over Large Chromosomal Regions in Cancers Include Multiple Genes Unrelated to Malignant Progression
31. Snus undermines quit attempts but not abstinence: a randomised clinical trial among US smokers
32. Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
33. Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
34. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
35. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
36. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
37. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
38. A longitudinal, naturalistic study of U.S. smokers' trial and adoption of snus
39. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner
40. Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases?
41. The Faculty Costs to Educate a Biomedical Sciences Graduate Student
42. Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality.
43. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
44. Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models
45. Understanding the role of advanced practice providers in oncology in the United States
46. Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells
47. Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells
48. Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis
49. Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice
50. KAT6A, a Chromatin Modifier from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.